<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747613</url>
  </required_header>
  <id_info>
    <org_study_id>CLNP023C12001B</org_study_id>
    <nct_id>NCT04747613</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <official_title>An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single arm, multicenter, roll-over extension study to&#xD;
      characterize long-term safety, tolerability and efficacy of iptacopan and to provide access&#xD;
      to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies&#xD;
      with iptacopan&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this phase 3 open-label, single arm, multicenter study is to evaluate the&#xD;
      long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide&#xD;
      access to patients who have completed (without tapering down) Phase 2 and Phase 3 trials and&#xD;
      derived benefit from iptacopan treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with adverse events</measure>
    <time_frame>60 months</time_frame>
    <description>Safety evaluations including but not limited to adverse events/serious adverse events, safety laboratory parameters, vital signs, etc. through End of Study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving sustained hemoglobin levels ≥ 12 g/dL in the absence of red blood cell transfusions</measure>
    <time_frame>60 months</time_frame>
    <description>Proportion of participants achieving sustained hemoglobin levels ≥ 12 g/dL in the absence of red blood cell transfusions evaluated over yearly intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who remain free from transfusions</measure>
    <time_frame>60 months</time_frame>
    <description>Proportion of participants who remain free from transfusions evaluated over yearly intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breakthrough hemolysis (BTH)</measure>
    <time_frame>60 months</time_frame>
    <description>Rate of breakthrough hemolysis (BTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Major Adverse Vascular Events MAVEs</measure>
    <time_frame>60 months</time_frame>
    <description>MAVEs (incl. thrombosis) evaluated over yearly intervals</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>Iptacopan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be receiving open label oral iptacopan 200 mg b.i.d monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iptacopan</intervention_name>
    <description>Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral</description>
    <arm_group_label>Iptacopan</arm_group_label>
    <other_name>LNP023</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male and female participants ≥ 18 years of age with a diagnosis of PNH who have&#xD;
             completed Phase 2 or Phase 3 clinical studies&#xD;
&#xD;
          -  Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and&#xD;
             Haemophilus influenzae infections&#xD;
&#xD;
          -  Per investigator's clinical judgement benefit from continued treatment with iptacopan&#xD;
             and has been clinically stable on iptacopan monotherapy for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who in the parent PNH studies either screen or baseline failed, or&#xD;
             prematurely withdrew from the study for any reason&#xD;
&#xD;
          -  Any comorbidity or medical condition (including but not limited to any active systemic&#xD;
             bacterial, viral or fungal infection or malignancy) that, in the opinion of the&#xD;
             investigator, could put the subject at increased risk or potentially confound study&#xD;
             data.&#xD;
&#xD;
          -  History of recurrent invasive infections caused by encapsulated organisms, such as&#xD;
             Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae&#xD;
&#xD;
          -  History of hematopoietic stem cell transplantation&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iptacopan</keyword>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria (PNH)</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Anemia</keyword>
  <keyword>LNP023</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

